摘要
新一轮国家基本药物政策改革的主要变化和调整是兼顾协调新医改公共性目标与医药产业利益的结果。基本药物数量的大大缩减,还原了基本药物"基本、基础、基层"的原本面貌,为改变以药养医的痼疾、降低医疗服务成本提供了制度基础。
In August 2009, a new round of national essential drug system construction was launched, whether this new round of essential drug system construction can get rid of the embarrassing situation faced by previous polices on national essential drugs has become the focus of common concern to all parties. Overall, the new essential drug list covers both reform goal of publicness of the new medical reform goals and interests of the pharmaceutical industry. Although the practical implementation of a range of issues will occur inevitably, it is foreseeable that this reform will contribute to the reform of public hospitals in the next step and healthy development of healthcare industry in China, and will even lead to another round of reshufffe in pharmaceutical industry.
出处
《中国处方药》
2010年第2期26-29,共4页
Journal of China Prescription Drug